TNXP Tonix Pharmaceuticals Holding Corp.
USHealthcareAs of 2026-07-10 16:00
Why TNXP matters now
Tonix Pharmaceuticals Holding Corp. (TNXP) is a US stock in Healthcare. The latest InvestLog snapshot shows $12.53 with -3.84% on the session and $199.7M in market capitalization; recent performance reads 1-month -12.40% and YTD -23.11%.
The latest financial table shown here is Q1 2026, with revenue of $6.9M, net income of $-40.2M, and EPS of $-2.93. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -69.3%.
The latest indexable market news headline is "Tonix Pharmaceuticals Announces First Patient Enrolled in Phase 2 HORIZON Study of TNX-102 SL for the Treatment of Major Depressive Disorder (MDD)" from GlobeNewsWire.
Additional event context on this page matters because analyst consensus is Buy with a median target of $—; recent insider activity includes Taylor Carolyn E. filing P-Purchase. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
0.72
P/S
10.90
EV/EBITDA
-0.05
DCF Value
$24.43
FCF Yield
-69.3%
Div Yield
0.0%
Margins & Returns
Gross Margin
52.6%
Operating Margin
-861.2%
Net Margin
-839.5%
ROE
-67.7%
ROA
-57.1%
ROIC
-66.2%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $6.9M | $-40.2M | $-2.93 |
| Q4 2025 | $5.4M | $-46.9M | $-4.28 |
| FY 2025 | $13.1M | $-124.0M | $-14.57 |
| Q3 2025 | $3.3M | $-32.0M | $-3.59 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$—
Target (Median)
$—
Target Range
$— - $—
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
1.68
Tonix Pharmaceuticals Holding Corp. is a biopharmaceutical firm primarily operating in the clinical development stage. Its overarching mission involves the discovery, acquisition, advancement, and commercialization of novel therapeutic agents and diagnostic tools, all aimed at combating human illnesses and easing patient discomfort. The company boasts a comprehensive pipeline of potential treatments spanning several key medical fields: immunology, rare conditions, infectious diseases, and central nervous system (CNS) disorders. In the realm of immunology, Tonix is progressing with biologics designed to address organ transplant rejection, various autoimmune diseases, and certain forms of cancer. A prominent candidate here is TNX-1500, a humanized monoclonal antibody targeting CD40-ligand, which is being investigated for its utility in preventing both allograft and xenograft rejection, as well as in treating autoimmune disorders. Its rare disease initiatives include TNX-2900, a specific treatment candidate for Prader-Willi syndrome. The infectious disease segment features a diverse array of programs: TNX-801, a vaccine designed to offer protection against smallpox and monkeypox. TNX-1840 and TNX-1850, which are live virus vaccines based on the company's recombinant pox vaccine (RPV) platform, targeting COVID-19. TNX-3500, a small molecule antiviral drug for the treatment of acute COVID-19. TNX-102 SL, a small molecule medication under investigation for Long COVID, a persistent post-acute COVID-19 condition. Finally, the CNS portfolio encompasses both small molecules and biologics intended to manage pain, neurological conditions, psychiatric ailments, and addiction. Notably, TNX-102 SL is also in mid-Phase 3 development for alleviating fibromyalgia symptoms. Other CNS candidates include TNX-1900, which is being developed to prevent migraine headaches, and TNX-1300, a biologic aimed at treating cocaine intoxication. The company was established in 2007 and maintains its headquarters in Chatham, New Jersey.